ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,512.35
0.54%
Dow Jones
39,392.88
0.58%
US Dollar vs MXN
18.28025
-0.84%
Brent Oil
84.655
-0.89%
Bitcoin
60,838.17
-1.25%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. MorphoSys AG (MOR)

  7. MorphoSys AG (MOR) Noticias

MOR

MorphoSys (MOR)

MorphoSys AG
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MOR
FechaHoraFuenteTítuloSímboloCompañía
20/06/202401:47Business WireMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority ShareholdersNASDAQ:MORMorphoSys AG
10/06/202410:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
04/06/202415:06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
29/04/202415:01Business WireMorphoSys AG Reports First Quarter 2024 Financial ResultsNASDAQ:MORMorphoSys AG
11/04/202407:39Business WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisNASDAQ:MORMorphoSys AG
13/03/202415:02Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
06/02/202405:14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:MORMorphoSys AG
10/12/202318:31Business WireMorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyNASDAQ:MORMorphoSys AG
20/11/202316:19Dow Jones NewsMorphoSys Trial for Blood-Cancer Treatment Reaches Primary EndpointNASDAQ:MORMorphoSys AG
20/11/202315:30Business WireMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionNASDAQ:MORMorphoSys AG
15/11/202315:01Business WireMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
09/08/202315:01Business WireMorphoSys AG Reports Second Quarter and First Half 2023 Financial ResultsNASDAQ:MORMorphoSys AG
03/05/202315:01Business WireMorphoSys AG Reports First Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
17/04/202306:37Business WireAprès cinq ans, MorphoSys et Incyte annoncent les résultats de l'étude L-MIND montrant des réponses prolongées et durables chez des patients atteints de LDGCB récidivant ou réfractaire traités par Monjuvi® (tafasitamab-cxix)NASDAQ:MORMorphoSys AG
17/04/202306:37Business WireMorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigenNASDAQ:MORMorphoSys AG
16/04/202314:01Business WireMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)NASDAQ:MORMorphoSys AG
15/03/202315:03Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
17/11/202215:25TipRanksJMP Securities Sticks to Its Buy Rating for Morphosys Ag (MOR)NASDAQ:MORMorphoSys AG
16/11/202215:01Business WireMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial ResultsNASDAQ:MORMorphoSys AG
14/11/202204:30Dow Jones NewsMorphoSys Shares Slide After Roche's Alzheimer's Drug Trial FailsNASDAQ:MORMorphoSys AG
11/08/202207:16TipRanksJ.P. Morgan Keeps Their Hold Rating on Morphosys Ag (MOR)NASDAQ:MORMorphoSys AG
04/08/202215:25TipRanksJMP Securities Thinks Morphosys Ag’s Stock is Going to RecoverNASDAQ:MORMorphoSys AG
03/08/202215:01Business WireMorphoSys AG Reports Second Quarter and First Half 2022 Financial ResultsNASDAQ:MORMorphoSys AG
15/06/202207:41PR Newswire (US)I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210NASDAQ:MORMorphoSys AG
14/06/202215:01Business WireMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210NASDAQ:MORMorphoSys AG
10/06/202202:15Business WireMorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022NASDAQ:MORMorphoSys AG
12/05/202209:45Business WireMorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual MeetingsNASDAQ:MORMorphoSys AG
05/05/202213:55TipRanksMorphosys Ag (MOR) Receives a Buy from JMP SecuritiesNASDAQ:MORMorphoSys AG
04/05/202215:01Business WireMorphoSys AG Reports First Quarter 2022 Financial ResultsNASDAQ:MORMorphoSys AG
16/03/202215:07Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
 Showing the most relevant articles for your search:NASDAQ:MOR

Su Consulta Reciente

NYSE
JPM
JP Morgan Chase
FX
EURUSD
Euro vs US Dollar
NYSE
CVX
Chevron
AMEX
XLE
Energy Select Sector SPDR
FX
EURMXN
Euro vs MXN
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BASFY
BASF (QX)
USOTC
ADDYY
Adidas (QX)
NASDAQ
GOOGL
Alphabet
AMEX
SPY
SPDR S&P 500
NASDAQ
AMZN
Amazon.com
NYSE
KO
Coca Cola
USI
USTECH100
US Tech 100
CCOM
SILVER
SILVER
CCOM
US500
US 500
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados